Redhill Biopharma Ltd (RDHL) — Cash Flow-to-Debt Ratio
Redhill Biopharma Ltd (RDHL) has a Cash Flow-to-Debt Ratio of -0.11x as of June 2025, meaning its operating cash flow of $-2.51 Million could theoretically repay 0% of its total liabilities ($22.79 Million) in one year. See RDHL financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Redhill Biopharma Ltd Cash Flow-to-Debt Ratio (2010–2025)
Historical debt coverage capacity for Redhill Biopharma Ltd across 16 annual periods. For the full cash flow conversion analysis, see Redhill Biopharma Ltd cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Redhill Biopharma Ltd (2010–2025)
Year-by-year debt coverage analysis for Redhill Biopharma Ltd. Check RDHL cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.46x | $-9.65 Million | $21.08 Million | ▼ -11.1% |
| 2024 | -0.41x | $-9.37 Million | $22.73 Million | ▲ +75.9% |
| 2023 | -1.71x | $-35.82 Million | $20.98 Million | ▼ -1112.7% |
| 2022 | -0.14x | $-29.18 Million | $207.27 Million | ▲ +62.7% |
| 2021 | -0.38x | $-65.05 Million | $172.31 Million | ▼ -29.3% |
| 2020 | -0.29x | $-48.58 Million | $166.38 Million | ▲ +89.9% |
| 2019 | -2.89x | $-40.75 Million | $14.10 Million | ▲ +5.8% |
| 2018 | -3.07x | $-34.46 Million | $11.22 Million | ▲ +15.8% |
| 2017 | -3.65x | $-44.77 Million | $12.28 Million | ▼ -48.5% |
| 2016 | -2.45x | $-28.26 Million | $11.51 Million | ▲ +7.0% |
| 2015 | -2.64x | $-17.83 Million | $6.75 Million | ▲ +17.0% |
| 2014 | -3.18x | $-12.23 Million | $3.85 Million | ▲ +9.0% |
| 2013 | -3.49x | $-8.44 Million | $2.42 Million | ▲ +44.6% |
| 2012 | -6.30x | $-6.79 Million | $1.08 Million | ▼ -88.0% |
| 2011 | -3.35x | $-4.69 Million | $1.40 Million | ▼ -2386.9% |
| 2010 | -0.13x | $-1.63 Million | $12.10 Million | — |